Overview

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

Status:
Recruiting
Trial end date:
2022-11-23
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, non-randomised, 3-arm (A, B, and C), drug-drug interaction study in patients with advanced solid tumours.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Parexel
Treatments:
Adavosertib
Itraconazole
Omeprazole
Rifampin